Biotechgate Global Database ›
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 2-4 February 2022
Bagsværd, Denmark, 4 February 2022 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
Members of Executive Management have participated in a long-term incentive programme consisting of a one-year performance period (2018) and a three-year vesting period (2019-2021). The shares allocated have on 2 February 2022 been transferred to current and former executives as specified below. No dividend has been paid to the executives during the one-year performance period or the three-year vesting period. For further information please see Novo Nordisk’s Remuneration Report 2021.
The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Maha Kutay | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Closely related to Kasim Kutay, member of the Board of Directors | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) | Description of the financial instrument, type of instrument, | Shares | |||
| Identification code | Novo Nordisk B DK0060534915 | ||||
| b) | Nature of the transaction | Purchase of shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 694.00 | 255 shares | ||||
| d) | Aggregated information
| 255 shares DKK 694.00 | |||
| e) | Date of the transaction | 2022-02-02 | |||
| f) | Place of the transaction | Nasdaq Copenhagen | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | President and CEO | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) | Description of the financial instrument, type of instrument, | Shares | |||
| Identification code | Novo Nordisk B DK0060534915 | ||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with long-term incentive programme) | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 76,619 shares | ||||
| d) | Aggregated information
| 76,619 shares DKK 0.00 | |||
| e) | Date of the transaction | 2022-02-03 | |||
| f) | Place of the transaction | Outside a trading venue | |||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | President and CEO | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) | Description of the financial instrument, type of instrument, | Shares | |||
| Identification code | Novo Nordisk B DK0060534915 | ||||
| b) | Nature of the transaction | Sale of shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 695.91 | 40,000 shares | ||||
| d) | Aggregated information
| 40,000 shares DKK 695.91 | |||
| e) | Date of the transaction | 2022-02-02 | |||
| f) | Place of the transaction | Nasdaq Copenhagen | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Maziar Mike Doustdar | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive vice president, International Operations | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) | Description of the financial instrument, type of instrument, | Shares | |||
| Identification code | Novo Nordisk B DK0060534915 | ||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with long-term incentive programme) | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 23,947 shares | ||||
| d) | Aggregated information
| 23,947 shares DKK 0.00 | |||
| e) | Date of the transaction | 2022-02-03 | |||
| f) | Place of the transaction | Outside a trading venue | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Karsten Munk Knudsen | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive vice president, Chief Financial Officer | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) | Description of the financial instrument, type of instrument, | Shares | |||
| Identification code | Novo Nordisk B DK0060534915 | ||||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with long-term incentive programme) | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 0.00 | 21,551 shares | ||||
| d) | Aggregated information
| 21,551 shares DKK 0.00 | |||
| e) | Date of the transaction | 2022-02-03 | |||
| f) | Place of the transaction | Outside a trading venue | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name of the Board member/Executive/Associated Person | Karsten Munk Knudsen | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Executive vice president, Chief Financial Officer | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) | Description of the financial instrument, type of instrument, | Shares | |||
| Identification code | Novo Nordisk B DK0060534915 | ||||
| b) | Nature of the transaction | Sale of shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 674.40 | 10,000 shares | ||||
By: GlobeNewswire
- 04 Feb 2022
Return to news
Partners
Upcoming Life Sciences Events
| |||||
